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The purpose of the presented investigations is to design, construct and
establish the characteristic performance of the Jagiellonian Positron Emis-
sion Mammography(J-PEM), being designed for the detection and diag-
nosis of breast cancer. Its construction is based on a novel idea of PET
tomography based on plastic scintillators and wavelength shifter (WLS)
and a new concept of positronium imaging. We have prepared a simulation
program based on Monte Carlo methods for optimizing the geometry and
material of the J-PEM prototype. Here we present the first results from
the simulations and a brief review of the state of art of breast imaging
modalities and their characteristics motivating our investigation.
PACS numbers: PACS numbers come here
1. Introduction
Breast cancer is the most common cancer and the leading cause of death
in females. A woman’s risk of developing invasive breast cancer in her life is
approximately 1 in 8 (12%) [1]. Diagnosis of breast cancer at earlier stages
can result in improved outcomes when followed by timely and appropriate
treatment, which allows for simpler and more cost-effective treatment to
reduce both morbidity and mortality. The main point of making a diagnos-
tic test is to decrease doctors doubt that a patient has a specific sickness,
to the degree that they can settle on the board choices [2]. There is basic
estimation of interpretation performance of screening tests which are based
on sensitivity, specificity, positive predictive value, and cancer stage at di-
agnosis [3]. Sensitivity and specificity describe what a test can and cannot
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tell us, respectively. Both are expected to completely comprehend a tests
qualities as well as its weaknesses.
In more detail, sensitivity is expressed in percentage and defines the
proportion of true positive subjects with the disease in a total group of
subjects with the disease (True Positive/(True Positive+False Negative)).
Sensitivity is defined as the probability of getting a positive test result in
subjects with the disease. Hence, it relates to the potential of a test to
recognise subjects with the disease [4].
Specificity is the number of true negative cases divided by the sum of
true negatives and false positives. In other words, specificity represents the
probability of a negative test result in a subject without the disease. There-
fore, we can postulate that specificity relates to the aspect of diagnostic
accuracy that describes the test ability to recognise subjects without the
disease, i.e. to exclude the condition of interest.
The positive predictive value is the likelihood of having invasive cancer if
one is recalled for assessment (true positive cases divided by the sum of the
true positive and false positive cases). A test that is highly sensitive will flag
almost everyone who has the disease and not generate many false-negative
results and a high-specificity test will effectively preclude nearly everyone
who does not have the disease and will not create many false-positive re-
sults [4]. Sensitivity and specificity is rather small for all the conventional
methods used for detection of breast cancer which leads to the problem
that, for women between ages 50 and 69 who go for the breast check-up,
around 10% of women are ill but not treated. Between 20 and 25% of
women, depending on the detection method, are wrongly diagnosed to have
a cancer which leads to unnecessary biopsies [5, 6]. Because of the small
dimensions of these lesions, a few millimeters in diameter, a detector system
for such application must have high sensitivity and good spatial resolution.
Nowadays in present imaging modalities, sensitivity is compromised in the
case of dense breasts, where it is difficult to distinguish between the tumor
and the normal tissues. Therefore, new diagnosis processes and systems for
breast cancer are the subject of much research effort. One such research
line relies on the use of Positron Emission based technology. This is the
case of the development of the J-PEM scanner, based on positron emission
mammography (PEM) system, which aims at the detection of tumors with
diameters down to 1 mm. The requirements for high sensitivity and good
spatial resolution can be fulfilled by J-PEM which combines wavelength
shifters along with plastic scintillators, compact photo-detectors, large an-
gular acceptance, depth-of-interaction (DOI) measurement capability and
efficient data acquisition systems.
In this paper the J-PEM prototype for positron emission mammography
is presented. Focus is given to the system design and preliminary results
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from simulations for the validation of the detection techniques and system
performance. In Section 2 we have described possible imaging modalities
with the given sensitivity and specificity. Nevertheless, neither sensitivity
nor specificity are influenced by the disease prevalence, meaning that results
from one study could easily be transferred to some other setting with a
different prevalence of the disease in the population. Nonetheless, sensitivity
and specificity can vary greatly depending on the spectrum of the disease in
the studied group [7]. Section 3 details the concept behind the J-PEM and
the possibilities of positronium imaging [8, 9]. Section 4 presents preliminary
results using Monte carlo simulation, performed using the GATE toolkit.
2. Screening test
The goal of screening asymptomatic women is to find breast cancer in
its earliest stages when treatment has the highest chance for survival. For
diagnosis and characterization of primary breast lesions, anatomical imaging
such as mammography is the most common screening test for breast cancer,
which is basically an x-ray picture of the breast. Examples of mammography
images are shown in Fig. 1 for a 67 year old patient. Mammography may
find tumors that are too small to feel. It may also find ductal carcinoma in
situ (DCIS) [10]. Mammography is more averse to discover breast tumors
in women with dense breast tissue. Since both tumors and dense breast
tissue seems white on a mammogram, it is hard to find a tumor when there
is a dense breast tissue. The mammography sensitivity varies in the range
depending on the age of the examined group and number. This range for
sensitivity varies from 80% to 96% and in case of specificity it is in the range
of 15 to 51.8% [11].
However there is also a novel technique developed in the last few years
based on the mammography methodology: contrast-enhanced spectral mam-
mography (CESM). This method, like MRI, is based on imaging of tumor
neoangiogenesis by use of a contrast agent [1, 13]. CESM uses a chelated
iodine-base x-ray contrast agent, while MRI uses a chelated gadolinium-
based paramagnetic agent [14, 15]. Because of high sensitivity of CESM
(similar to sensitivity of MRI) this technique maybe comparable with MRI
in some cases. CESM, like other diagnostic methods, has some limitations.
Benign lesions enhance on CESM, just as they do on MRI. That is, there
is no possibility to generate a time-enhancement curve, comparable to that
in breast MRI [11, 16]. Just as with mammography, CSEM sensitivity
and specificity also varies depending on the age of the examined group and
number. Sensitivity and specificity varies from 92.7% to 100% and 41% to
69.7%, respectively [11]. Exemplary CSEM images for CC and MLO views
are shown in Fig. 2.
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Fig. 1. Example of mammography images. Patient 67y/o. Left side CC (cranio-
caudal) views; Right side MLO (mediolateral) views of both breasts. In the right
breast, upper outer quadrant, approx. 6 cm from the nipple cluster of microcal-
cifications is visible (50x70mm). In the background of these microcalcifications
well circumscribed, dense area (diameter 20mm) is present. BI-RADS cat.V. This
image is provided by Maria Sklodowska-Curie Memorial Institute of Oncology in
Cracow, Poland.
Fig. 2. Example of CESM images of the same 67 y/o patient as on Fig 1, left side
CC (cranio-caudal) views; right side MLO (mediolateral) views of both breasts.
Right breast, upper outer quadrant, pathological contrast enhancement area is
visible (dimensions 110x75 mm). BI-RADS category V. This image was provided
by Maria Sklodowska-Curie Memorial Institute of Oncology in Cracow, Poland.
Digital breast tomosynthesis (DBT) is a promising new technology for
acquiring and displaying three-dimensional mammograms [17]. Because of
its improved ability to differentiate true breast lesion or summation of nor-
mal breast structures. An example image of tomosynthesis is shown in
Fig. 3, for the different planes, it has improved characterization of masses.
Tomosynthesis is increasingly being used in the diagnostic setting to eval-
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uate masses, asymmetries, and architectural distortion. Tomosynthesis can
be done in full or spot compression views as needed [18]. The sensitivity
and specificity of DBT ranged from 74.2% to 86.9% and 97.0% to 97.5%,
respectively [19].
Fig. 3. Example of Tomosynthesis planes of 29 y/o patient - in the planes there
are numerous well limited shadows architectural distortion and microcalcifications
on histopathology - papillary carcinoma in the right breast. Breast thickening ob-
served for 3 years. The right breast ultrasound, visualized numerous solid and fluid
lesions. This image was provided by Maria Sklodowska-Curie Memorial Institute
of Oncology in Cracow, Poland.
Ultrasound is well accepted as the most useful adjunct to mammography
for the diagnosis of breast abnormalities. An exemplary ultrasound image
of right breast of a patient is shown in Fig. 4. Ultrasound is most often used
to assess palpable masses and nonpalpable masses that have been detected
during screening mammography [20, 21]. Ultrasound may demonstrate ma-
lignancies and other masses that are not visible mammographically [22].
Ultrasound had an overall pooled sensitivity and specificity of 80.1% and
88.4%, respectively [11].
Molecular breast imaging (MBI) is a nuclear medicine technique that
uses dedicated gamma cameras to image the physiologic uptake of a radio-
pharmaceutical, typically 99mTc-sestamibi, in the breast. MBI is capable
of detecting mammographically occult cancers, particularly in women with
dense breasts [23, 24]. MBI has an overall sensitivity of 90%, with a sensi-
tivity of 82% for lesions less than 10 mm in size [25].
Magnetic resonance imaging (MRI) has been used as an adjunctive
screening tool, mainly for women who may be at increased risk for the
development of breast cancer. Example images of MRI are shown in fig. 5
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Fig. 4. Example image of breast ultrasound (the same patient as on Fig.1). Right
breast, outer upper quadrant, 7cm from the nipple not well defined hypoechogenic
area (dimensions: 24x20mm) is visible. BI-RADS category IV c. This image was
provided by Maria Sklodowska-Curie Memorial Institute of Oncology in Cracow,
Poland.
with T1 contrast enhancement. MRI for screening has not been very pop-
ular in women with average risk due to concerns about the low specificity
leading to additional biopsies, time and cost of technology [26]. Breast MRI
sensitivity values reported in high risk screening studies range from 93% to
99%. Despite its high sensitivity, breast MRI has been reported to have
variable specificity, ranging from 50% to 85% [27]. These number of sensi-
tivity and specificity depends on the type of tumor, size of tumor, age of
patient, and where it is localised.
Then there is positron emission mammography which is a new tech-
nology that is designed for the imaging of specific small body parts. To
achieve high resolution it uses short-lived positron-emitting isotopes to gen-
erate images of cancer within the breast [28]. It has better specificity as
compared to MRI, which confines the unneeded biopsies. The potential ba-
sis for the improved sensitivity of PEM is enhanced spatial resolution [30],
which enables detection of small lesions. This is our motivation for develop-
ing J-PEM. PEM has a higher imaging sensitivity in small tumors < 2 cm.
Even in very small tumors < 1 cm, the imaging sensitivity was acceptable
at 60-70% [30]. The standard sensitivity and specificity of PEM is 80% and
100%, respectively [29].
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Fig. 5. Example images of breast MRI (MIP, subtraction T1 contrast enhanced
image, T1 contrast image with fat saturation). This image is provided by Maria
Sklodowska-Curie Memorial Institute of Oncology in Cracow, Poland.
3. Concept of J-PEM
The J-PEM is a prototype intended to evaluate PET technology in the
diagnosis of malign neoplasm in the breast and of ganglion loco-regional
invasion. It is based on plastic scintillators and utilizes the same tech-
nology as the Jagiellonian Positron Emmision Tomograph, J-PET [31]. It
is optimized for the detection of photons from electron-positron annihila-
tion [32, 33]. Such photons, having an energy of 511 keV, interact with elec-
trons in plastic scintillators predominantly via the Compton effect. J-PEM
uses a dedicated instrument for breast cancer detection that is equipped
with two parallel photon detectors in a configuration similar to mammog-
raphy compressors. The detector system consists of two modules of plastic
scintillators, with each module built from two layers of plastic scintillator
and the wavelength shifters [34, 35] placed orthogonally between them, as
shown in Fig. 6. Each scintillator bar is attached at both ends with Silicon
Photomultipliers for the signal readout [32]. The combined use of plastic
scintillators, which have superior timing properties, with the WLS strips
can provide an affordable and precise scanner with significant improvement
in spatial resolution and efficiency for the detection of breast cancer. Plas-
tic scintillators are characterized by short light decay time which is in the
order of 1.5 ns [32]. This enables one to achieve high time resolution. In the
J-PET, solution for the position of the interaction point of photons is based
on the measurement of the time of the signals arrival to the ends of the long
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scintillator strips. So far a resolution of about 10 mm was achieved [35].
In order to achieve high resolution, we propose to register scintillation light
escaping the scintillator bar through a side wall using an array of WLS. It
has been already proven that one can reach to position resolution of 5 mm
for the coordinate along the scintillator bar. J-PET is capable of performing
Fig. 6. Top figure: Geometry scheme of J-PEM used in GATE simulation. Here
blue color represents plastic scintillators and green color represents wavelength
shifters. Dimension of plastic scintillators and WLS were 6x24x500 mm and
3x10x100 mm, respectively. Space between the modules is 33.88 cm. Bottom
Left and right are the Y-Z and X-Y plane view of the given geometry for single
module.
simultaneous imaging of the density distribution of annihilation points as
well as positron annihilation lifetime spectroscopy [8, 36]. The positronium
imaging technique has successfully distinguished cancer from healthy tissue
by in vitro probing of human tissues or in the in vitro organoid (3D cell
culture) systems [37]. Study of positronium decay can provide new data in
medical diagnosis as the mean lifetime of positronium depends on the size
of free volume between atoms, whereas its formation probability depends on
the concentration of voids [38]. In the free space between atoms, positronium
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decays as it does in vacuum [8]. However, within molecules there are addi-
tional annihilation possibilities and the mean lifetime of ortho-positronium
decreases significantly compared with the lifetime in vacuum, from 142 ns
to a few nanoseconds [39]. The reconstruction of positronium lifetime re-
quires determination of times of its creation and annihilation. These can be
achieved when applying radiopharmaceuticals labeled with isotopes such as
Scandium-44 which after emission of the positron changes into a daughter
nucleus in an excited state [9]. A technique that combines PALS and PET
in clinical use must enable determination of positronium parameters in a
position-sensitive manner, and it needs to be scaled to work for living or-
ganisms. Recently, a first possible solution designed for the size of a human
body was proposed. In vitro studies comparing the positronium properties
in cancerous and healthy tissues suggest that the ortho-positronium mean
lifetime is correlated with the grade of development of metabolic disorders
in cancer cells [38, 39]. Combining the information about metabolism with
information about the structure of tissue will improve specificity and sensi-
tivity, therefore increasing the accuracy of the examination.
4. Monte Carlo simulation
In order to quantify the J-PEM geometry we have performed Monte-
Carlo simulations. The simulations were performed using the GATE pack-
age. GATE (Geant4 Application for Tomographic Emission) is a Monte
Carlo simulation platform developed by the Open-GATE collaboration [40]
based on Geant4 software. It is dedicated to numerical simulations in med-
ical imaging and radiotherapy. It utilizes an easy macro mechanism to
configure the experimental settings for computed tomography, single pho-
ton emission computed tomography, positron emission tomography as well
as optical imaging (bioluminescence and fluorescence) or radiotherapy. In
the simulations the full geometry of the J-PEM detector and the compo-
sition of the detector material were taken into account. The interactions
of photons in the scintillators were simulated by GATE. In the simulations
we assumed that annihilation source is placed in the center of the detector
and that the back-to-back photons (each with energy of 511 keV) from the
Ps→ 2γ annihilation are isotropically emitted. Energy deposition inside the
plastic scintillator is shown in Fig.7. According to the performed simulation
we are able to register 4.33% of generated back to back events. After adding
the condition that both photons deposited at least 200 keV energy fraction
of register annihilation drop to 0.8 % . Such a condition is needed for the
suppression of the scatter fraction [41]. We found that there was 11.3%
primary back-to-back registered events where at least one photon scattered
in WLS. The J-PEM simulation will be used to evaluate the performance of
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Fig. 7. Top left : Shows the number of interactions per scintillator ID for back to
back photons.Top right: Shows the number of interactions per scintillator ID for
back to back photons with condition that both photons deposited at least 200 keV
energy. Scintillators in the inner and outer layer of upper module are numbered
from 1 to 13 and 14 to 26, respectively. While, WLS in the upper module are
numbered from 27 to 67. Scintillators in the inner and outer layer of down module
are numbered from 68 to 81 and 82 to 94, respectively. WLS numbering for down
module are from 95 to 135. Figure in bottom shows energy deposition of primary
photons.
various detector configurations and options. Sensitivity estimations, study
of the depth-of-interaction measurement technique and estimation of the
background rates are some examples of basic information to be obtained
from the simulation and that is needed to finalize the detector concept.
Finally, simulated events will also be used as input to the reconstruction
software.
5. Conclusion
In this paper we have investigated the design, construction and establish-
ment of the characteristic performance of the Jagiellonian Positron Emission
Mammography (J-PEM) for the detection and diagnosis of breast cancer.
Its construction is based on a novel idea of PET based on plastic scintillators
and wavelength shifter (WLS) and a new concept of positronium imaging.
We have prepared a simulation program based on Monte Carlo method us-
ing GATE toolkit, for optimizing the geometry and material for the J-PEM
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prototype. We have also presented the first results from the simulations and
a brief review of the state of art of breast imaging modalities and their char-
acteristics motivating our investigation. Results from the simulations are
showing that the amount of registered back to back events are comparable
to those of conventional secondary screening methods for breast cancer [42],
thus making J-PEM a viable tool in early detection of cancer.
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